NCT07096843 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
| NCT ID | NCT07096843 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Climb Bio, Inc. |
| Condition | Primary Membranous Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 45 participants in total. It began in 2025-08-25 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of PMN with positive anti-PLA2R antibodies * CD19+ B cell count ≥40 cells/μL * UPCR ≥2.0 g/g * eGFR ≥35 mL/min/1.73 m² * Stable RAAS inhibitor therapy * Blood pressure \<150/90 mmHg at baseline * Adequate hematologic, hepatic, and renal function * Willing to use effective contraception (both sexes) * Other inclusion criteria may apply Exclusion Criteria: * Secondary Membranous Nephropathy * Rapidly progressive glomerulonephritis or other glomerulopathies * Prior B cell-depleting therapy within 24 weeks * Recent use of immunosuppressants * Active or high-risk infections * History of malignancy * Pregnancy or breastfeeding * Recent major surgery or hospitalization * Other exclusion criteria may apply
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07096843 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Primary Membranous Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07096843 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07096843 currently recruiting?
Yes, NCT07096843 is actively recruiting participants. Contact the research team at clinicaltrials@climbbio.com for enrollment information.
Where is the NCT07096843 trial being conducted?
This trial is being conducted at Denver, United States, Orlando, United States, Atlanta, United States, Indianapolis, United States and 11 additional locations.
Who is sponsoring the NCT07096843 clinical trial?
NCT07096843 is sponsored by Climb Bio, Inc.. The trial plans to enroll 45 participants.